Ocugen, INC 8-K filings

Ocugen reports significant progress in its gene therapy pipeline for blindness diseases, including FDA clearance for a Phase 3 trial and a substantial financing round.

Ocugen, Inc. has signed a binding term sheet with Roots Pharmaceutical for the exclusive rights to its OCU400 gene therapy in the Middle East and North Africa.

Ocugen, Inc. successfully concluded its 2026 Annual Meeting, confirming director elections, auditor ratification, and executive compensation frequency.

Ocugen, Inc. announced the resignation of its Chief Accounting Officer, Ramesh Ramachandran, effective May 29, 2026, with CFO Rita Johnson-Greene appointed as the principal accounting officer.

Ocugen, Inc. reported the departure of its Chief Medical Officer, Huma Qamar, and the appointment of Mohamed Genead as Acting/Interim Chief Medical Officer, effective May 8, 2026.

Ocugen, Inc. announced the completion of its private offering of $115 million in 6.75% Convertible Senior Notes due 2034, with net proceeds of approximately $99.5 million.

Ocugen announced the pricing of $115 million in convertible senior notes and provided a business update with Q1 2026 financial results, highlighting clinical trial progress and extended cash runway.

Ocugen, Inc. announced its intention to offer $115 million in convertible senior notes due 2034 to qualified institutional buyers, with plans to use proceeds for debt repayment and general corporate purposes.

Ocugen, Inc. announced positive 12-month topline data from its Phase 2 ArMaDa clinical trial for OCU410, a gene therapy for geographic atrophy, showing a statistically significant reduction in lesion growth.

Ocugen, Inc. announced the partial exercise of warrants by an institutional investor, generating $15 million and extending its cash runway into the first quarter of 2027.

Ocugen, Inc. has filed a petition in Delaware Chancery Court to validate a 2024 stockholder vote to increase authorized shares and subsequent share issuances, following a legal challenge.

Ocugen, Inc. announced its fourth quarter and full year 2025 financial results alongside significant progress in its gene therapy clinical trials for blindness diseases.

Ocugen, Inc. announced the appointment of Rita Johnson-Greene as its new Chief Financial Officer, effective February 9, 2026.

Ocugen, Inc. announced the closing of its underwritten offering of 15 million common shares, securing $20.85 million in net proceeds to extend its cash runway into Q4 2026.

Ocugen, Inc. announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at $1.50 per share, aiming to raise approximately $20.8 million in net proceeds for general corporate purposes.

Ocugen announced positive preliminary 12-month data from its Phase 1 and Phase 2 ArMaDa trials for OCU410, a gene therapy for geographic atrophy.

Ocugen's Board approved a significant performance-restricted stock unit award for CEO Dr. Shankar Musunuri, tied to regulatory and stock performance milestones.

Ocugen, Inc. reported its third quarter 2025 financial results, highlighted by clinical trial progress for its gene therapies, a new licensing agreement for OCU400 in South Korea, and a $20 million capital raise.

Ocugen's planned merger of its OrthoCellix subsidiary with Carisma Therapeutics has been terminated due to a failure to secure the required $25 million concurrent investment.

Ocugen, Inc. has entered into an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for its OCU400 gene therapy in the Republic of Korea, including an upfront payment, milestones, and royalties.

Ocugen, Inc. has entered into a subscription agreement to invest $5.0 million in Carisma Therapeutics Inc. as part of a larger concurrent investment tied to the previously announced merger of Ocugen's OrthoCellix subsidiary with Carisma.

Ocugen, Inc. announced a $20 million registered direct offering of common stock and accompanying warrants to an institutional investor, strengthening its financial position.

Ocugen, Inc. reported second quarter 2025 financial results, highlighted significant progress in its late-stage gene therapy clinical trials, and announced strategic initiatives including a proposed reverse merger and an exclusive licensing agreement for OCU400 in Korea.

Ocugen, Inc. announced that the U.S. District Court for the Eastern District of Pennsylvania granted its motion to dismiss a previously disclosed securities class action lawsuit with prejudice.

Ocugen, Inc. announced it has successfully regained compliance with Nasdaq's minimum bid price requirement, closing the previously reported listing deficiency.

Ocugen, Inc. has been granted an additional 180 calendar days, until December 29, 2025, to regain compliance with Nasdaq's minimum $1.00 bid price requirement, following a previous non-compliance notice.

Carisma Therapeutics Inc. and OrthoCellix, Inc., a wholly-owned subsidiary of Ocugen, Inc., have entered into a definitive merger agreement to create a Nasdaq-listed company focused on late clinical-stage regenerative cell therapies for orthopedic diseases, primarily NeoCart.

Ocugen, Inc. has filed an 8-K announcing the release of a new presentation showcasing promising clinical trial data for its ophthalmic treatment, demonstrating statistically significant improvements in visual function.

Ocugen, Inc. announced a binding term sheet for the exclusive Korean rights to its OCU400 modifier gene therapy for retinitis pigmentosa, alongside the election of two Class II directors and one Class III director at its 2025 Annual Meeting of Stockholders.

Ocugen reports progress in its gene therapy programs, including OCU400 for retinitis pigmentosa and OCU410ST for Stargardt disease, alongside its first quarter 2025 financial results.